Qure.ai’s AI-powered tools are designed to streamline patient care. Credit: raker / Shutterstock.

Global healthcare AI provider Qure.ai has obtained Health Canada’s Class III medical device licence for its suite of medical imaging AI solutions.

This authorisation allows the company to introduce its AI-powered tools to the Canadian healthcare market, aimed at supporting clinicians in delivering enhanced patient care.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Health Canada’s Class III classification is indicative of a thorough evaluation process, affirming the safety, effectiveness and quality of Qure.ai’s AI solutions.

As the highest risk category for software-as-a-medical device (SaMD) products, this classification highlights the sophisticated capabilities and stringent safety protocols of Qure.ai’s algorithms in the field of medical imaging.

The solutions provided by Qure.ai are engineered to support diagnostic precision and efficiency, contributing to improved patient outcomes through the early detection of medical conditions.

See Also:

The Class III licence encompasses all of Qure.ai’s principal offerings, including qXR, an AI tool for chest X-ray analysis that can detect a range of abnormalities and prioritise cases for review.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Other solutions include qCT, which aids in lung nodule management on chest CT scans for lung cancer screening and monitoring; and qER to assist in the quick identification of strokes, traumatic brain injuries, and other neurological issues.

Additionally, Qure.ai’s solutions facilitate the accurate detection and measurement of endotracheal and tracheostomy tube placements, identification of pneumothorax, and triaging of critical findings with precision using plain film chest radiography.

The Qure app enhances lung cancer and radiology workflows, enabling clinicians to remotely view and diagnose scans from X-rays, CT, MR, and more.

These AI-powered tools are designed to streamline patient care, provide critical alerts, and support early intervention, improving outcomes in both prehospital and emergency settings.

Qure.ai co-founder and CEO Prashant Warier said: “Receiving the Class III licence from Health Canada is a testament to the rigor and quality of our AI algorithms.

“This approval allows us to bring our already globally proven AI solutions to the Canadian healthcare market, where we can support healthcare professionals in making earlier, more accurate and efficient diagnoses. This puts patient care at the heart of digital healthcare transformation.”

In 2022, the US Food and Drug Administration (FDA) granted 510(k) clearance to Qure.ai’s AI algorithm, qXR-BT.